The prognostic significance of the biomarkers p21(WAF1/CIP1), p53, and bcl-2 in laryngeal squamous cell carcinoma

Cancer

Volumn 82, Issue 11, 1998, Pages 2159-2165

  Jin, Ying Tai ^a   Kayser, Scott ^b   Kemp, Bonnie L ^b   Ordonez, Nelson G ^b   Tucker, Susan L ^b   Clayman, Gary L ^b   Goepfert, Helmuth ^b   Luna, Mario A ^b   Batsakis, John G ^b   El Naggar, Adel K ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Flow cytometry; Larynx; Oncogenesis; Squamous cell carcinoma; Suppressor genes

Indexed keywords

BIOLOGICAL MARKER; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032102520     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2159::AID-CNCR10>3.0.CO;2-T     Document Type: Article

References (50)

1. Batsakis JG. Tumors of head and neck: clinical and pathological considerations. Baltimore: Williams and Wilkins, 1979: 574.
2. American Cancer Society. Cancer statistics. Atlanta: American Cancer Society, 1988:14-5.
3. Eiband JD, Elias EG, Suter CM, Gray WC, Didolkar MS. Prognostic factors in squamous cell carcinoma of the larynx. Am J Surg 1989;158:314-7.
4. Wiernik G, Millard PR, Haybittle JL. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology 1991; 19:411-7.
5. Pradier R, Gonzalez A, Matos E, Loria D, Adan R, Saco P, et al. Prognostic factors in laryngeal carcinoma: experience in 296 male patients. Cancer 1993;71:2472-6.
6. Davis RK. Prognostic variables in head and neck cancer tumor site, stage, nodal status, differentiation, and immune status. Otolaryngol Clin North Am 1985;18:411-9.
7. Goldsmith MM, Pillsbury HC. Pathologic and cytometric indicators of biologic behaviors in laryngeal cancers. In: Silver CE, editor. Laryngeal cancer. New York: Thieme Medical Publisher, 1991:27-32.
8. Kropveld A, Slootweg PJ, van Mansfeld ADM, Blankenstein MA, Hordijk GJ. Radioresistance and p53 status of T2 laryngeal carcinoma. Cancer 1996;78:991-7.
9. Pignataro L, Capaccio P, Pruneri G, Carboni N, Fracchiolla NS, Richelda R, et al. p53 and cyclin D1 protein expression in glottic laryngeal squamous cell carcinomas involving the anterior commissure (pT1bN0M0). Int J Oncol 1996;9:553-7.
10. Chaudhary KS, Lu QL, Abel PD, Khandan-Nia N, Shoma AM, El Baz M, et al. Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder. Br J Urol 1997;79:78-84.
11. Tzardi M, Kouvidou C, Panayiotides I, Stefanaki K, Rontogianni D, Zois E, et al. p53 protein expression in non-Hodgkin's lymphoma - comparative study with the wild type p53-induced proteins MDM2 and p21/WAF1. J Clin Pathol Clin Mol Pathol 1996;49:278-82.
12. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, et al. Bcl-2 and p53 expression in node-negative breast carcinoma-a study with long-term follow-up. Hum Pathol 1996;27:1149-55.
13. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyer AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1996;122:627-32.
14. Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M, Stell PM, et al. Elevated p53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer 1991;64:573-7.
15. Shin DM, Kin J, Ro JY, Hittelman J, Roth JA, Hong WK, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54: 321-6.
16. El-Naggar AK, Lai S, Luna MA, Zhou XD, Weber RS, Goepfert H, et al. Sequential p53 mutation analysis of pre-invasive and invasive head and neck squamous carcinoma. Int J Cancer 1995;64:196-201.
17. Coates P, Save V, Ansari B, Hall PA. Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. J Pathol 1995; 176:19-26.
18. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
19. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
20. 1 cyclin-dependent kinases. Cell 1993;75:805-16.
21. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
22. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinase controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
23. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971-81.
24. Calzolari A, Chiarelli I, Bianchi S, Messerini L, Gallo O, Porfirio B, et al. Immunohistochemical vs molecular biology methods: complementary techniques for effective screening of p53 alterations in head and neck cancer. Am J Clin Pathol 1997;107:7-11.
25. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226:1097-9.
26. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
27. Reed JC. bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
28. Steck KD, McDonnell TJ, El-Naggar AK. Flow cytometric analysis of apoptosis and bcl-2 in human solid neoplasms. Cytometry 1995;20:154-61.
29. Chen FF, Yan JJ, Jin YT, Su, IJ. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 1996;27:1089-92.
30. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, et al. The Bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
31. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
32. Strasser A, Harris AW, Jacks T, Gory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53 independent mechanisms inhabitable by Bcl-2. Cell 1994; 79:329-39.
33. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 and p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
34. Hsu SM, Raine L, Franger H. Use of an avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
35. Hedley DW, Friedlander M, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content: a paraffin-embedded pathological materials using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
36. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res 1996; 2:1591-9.
37. Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, et al. p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 1992;52:178-82.
38. Anwar K, Nakakuki K, Imai H, Naiki H, Inuzuka M. Overexpression of p53 protein in human laryngeal carcinoma. Int J Cancer 1993;53:952-6.
39. Ambros RA, Ross JS, Kallakury BV, Malfetano J, Kim Y, Hwang J, et al. p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Pathol 1995;8:441-5.
40. Melhem MF, Law JC, El-Ashmawy L, Johnson JT, Landreneau RJ, Srivastava S, et al. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am J Pathol 1995;146:1170-7.
41. Xu L, Chen YT, Huvos AG, Zlotolow IM, Rettig WJ, Old LJ, et al. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 1994;3:83-92.
42. Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphisms in the p53, p21, and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 1996;68: 420-3.
43. Lee WY, Jin YT, Tzeng CC. Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Res 1996;16: 3007-12.
44. Gorczyca W, Merkiewski M, Kram A, Tuziak T, Damagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinoma: their correlation with Ki-67 growth faction. Virchows Arch 1995;426:229-33.
45. Hurlimann J, Larrinaga B, Vala DLM. Bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;26:163-8.
46. Resnick JM, Uhlman D, Niehans GA, Gapany M, Adams G, Knapp D, et al. Cervical lymph node status and survival in laryngeal carcinoma: prognostic factors. Ann Otol Rhinol Laryngol 1995;104:685-94.
47. Chauvel P, Courdi A, Gioanni J, Vallicioni J, Santini J, Demard F. The labelling index: a prognostic factor in head and neck carcinoma. Radiother Oncol 1989;14:231-7.
48. Tomasino RM, Daniele E, Bazan V, Morello V, Tralongo V, Nuara R, et al. Prognostic significance of cell kinetics in laryngeal squamous cell carcinoma: clinicopathological associations. Cancer Res 1995;55:6103-8.
49. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, et al. p53 mutation and locoregional treatment failure and neck squamous carcinoma. J Natl Cancer Inst 1996;88:1580-6.
50. Raybaud-Diogène H, Fortin A, Morency R, Monteil RA, Tètu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol 1997;15:1030-8.